{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:11Z","timestamp":1792813391333,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01EB031830"],"award-info":[{"award-number":["R01EB031830"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA276240"],"award-info":[{"award-number":["R01CA276240"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM137901"],"award-info":[{"award-number":["R35GM137901"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118274","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:27:09Z","timestamp":1750130829000},"page":"118274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3622-9388","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9455-118X","authenticated-orcid":false,"given":"Mashael F.","family":"Aldossari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-9544","authenticated-orcid":false,"given":"Arshad J.","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyun","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6086-6561","authenticated-orcid":false,"given":"Sunny H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5223-1657","authenticated-orcid":false,"given":"Thuc Oanh","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasarao","family":"Singireddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5049-2023","authenticated-orcid":false,"given":"Zekun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanteng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Wen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-2899","authenticated-orcid":false,"given":"Fariborz","family":"Nasertorabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-9445","authenticated-orcid":false,"given":"Benjamin B.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-8557","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2025.118274_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2025.118274_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118274_bib3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/14712598.2016.1161753","article-title":"Antibody-drug conjugates for non-oncological indications","volume":"16","author":"Liu","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118274_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.biopha.2025.118274_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118274_bib6","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/anie.201410049","article-title":"Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody","volume":"54","author":"Zhang","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"14","key":"10.1016\/j.biopha.2025.118274_bib7","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.biochem.0c00046","article-title":"Rational design of a humanized antibody inhibitor of cathepsin B","volume":"59","author":"Dai","year":"2020","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.biopha.2025.118274_bib8","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","article-title":"Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress","volume":"26","author":"Yao","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.biopha.2025.118274_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2025.118274_bib10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/cb4004749","article-title":"An antibody CDR3-erythropoietin fusion protein","volume":"8","author":"Zhang","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118274_bib11","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/pro.3913","article-title":"A humanized antibody inhibitor for cathepsin L","volume":"29","author":"Shi","year":"2020","journal-title":"Protein Sci."},{"issue":"40","key":"10.1016\/j.biopha.2025.118274_bib12","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1073\/pnas.1211023109","article-title":"Synthesis of site-specific antibody-drug conjugates using unnatural amino acids","volume":"109","author":"Axup","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.biopha.2025.118274_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131177","article-title":"Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency","volume":"10","author":"Beerli","year":"2015","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.biopha.2025.118274_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1021\/acs.bioconjchem.7b00046","article-title":"Inducible, site-specific protein labeling by tyrosine oxidation-strain-promoted (4 + 2) cycloaddition","volume":"28","author":"Bruins","year":"2017","journal-title":"Bioconjugate Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118274_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chembiol.2017.02.012","article-title":"Stable and Potent Selenomab-Drug Conjugates","volume":"24","author":"Li","year":"2017","journal-title":"Cell Chem. Biol."},{"issue":"6325","key":"10.1016\/j.biopha.2025.118274_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1126\/science.aal3316","article-title":"Redox-based reagents for chemoselective methionine bioconjugation","volume":"355","author":"Lin","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2025.118274_bib17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41467-017-01257-1","article-title":"Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates","volume":"8","author":"Nanna","year":"2017","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.biopha.2025.118274_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba6752","article-title":"Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases","volume":"6","author":"Dai","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2025.118274_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jconrel.2021.06.041","article-title":"Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy","volume":"336","author":"Dai","year":"2021","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.biopha.2025.118274_bib20","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1021\/bc4002695","article-title":"Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation","volume":"24","author":"Okeley","year":"2013","journal-title":"Bioconjugate Chem."},{"issue":"9","key":"10.1016\/j.biopha.2025.118274_bib21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1021\/bc900434c","article-title":"Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes","volume":"21","author":"Wakankar","year":"2010","journal-title":"Bioconjugate Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118274_bib22","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.4161\/mabs.29889","article-title":"Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar","volume":"6","author":"Zhu","year":"2014","journal-title":"mAbs"},{"issue":"34","key":"10.1016\/j.biopha.2025.118274_bib23","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.1039\/D0SC01795G","article-title":"A poly-ADP-ribose polymer-based antibody-drug conjugate","volume":"11","author":"Shi","year":"2020","journal-title":"Chem. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118274_bib24","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1021\/acs.bioconjchem.5b00359","article-title":"Genetically encoded azide containing amino acid in mammalian cells enables site-specific antibody-drug conjugates using click cycloaddition chemistry","volume":"26","author":"VanBrunt","year":"2015","journal-title":"Bioconjugate Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118274_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4924","article-title":"Synthesis of site-specific Fab-drug conjugates using ADP-ribosyl cyclases","volume":"33","author":"Kim","year":"2024","journal-title":"Protein Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118274_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/biom10050764","article-title":"Site-specific antibody-drug conjugates in triple variable domain fab format","volume":"10","author":"Hwang","year":"2020","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.biopha.2025.118274_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118274_bib28","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1039\/D1SC05243H","article-title":"A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides","volume":"13","author":"Zacharias","year":"2022","journal-title":"Chem. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118274_bib29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-20-0166","article-title":"Dolaflexin: a novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect","volume":"20","author":"Yurkovetskiy","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"44","key":"10.1016\/j.biopha.2025.118274_bib30","doi-asserted-by":"crossref","first-page":"8337","DOI":"10.1039\/C8SC03899F","article-title":"Facile chemoenzymatic synthesis of a novel stable mimic of NAD","volume":"9","author":"Dai","year":"2018","journal-title":"Chem. Sci."},{"issue":"40","key":"10.1016\/j.biopha.2025.118274_bib31","doi-asserted-by":"crossref","first-page":"27629","DOI":"10.1074\/jbc.M109.030965","article-title":"Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38","volume":"284","author":"Graeff","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2025.118274_bib32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.chembiol.2008.08.007","article-title":"Covalent and noncovalent intermediates of an NAD utilizing enzyme, human CD38","volume":"15","author":"Liu","year":"2008","journal-title":"Chem. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118274_bib33","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1021\/jacsau.4c00695","article-title":"Nicotinamide riboside and CD38: covalent inhibition and live-cell labeling","volume":"4","author":"Kao","year":"2024","journal-title":"JACS Au"},{"issue":"18","key":"10.1016\/j.biopha.2025.118274_bib34","first-page":"4055","article-title":"Constitutive and antibody-induced internalization of prostate-specific membrane antigen","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118274_bib35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ijc.2910620511","article-title":"Jr., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids","volume":"62","author":"Troyer","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118274_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.biopha.2025.118274_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115966","article-title":"A systematic review on the current status of PSMA-targeted imaging and radioligand therapy","volume":"263","author":"Capasso","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118274_bib38","article-title":"Rational design of humanized antibody inhibitors for cathepsin S","author":"Yu","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2025.118274_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121129","article-title":"Expanding the toolbox of exosome-based modulators of cell functions","volume":"277","author":"Cheng","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2025.118274_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.01.025","article-title":"Genetically reprogrammed exosomes for immunotherapy of acute myeloid leukemia","author":"Zhang","year":"2025","journal-title":"Molecular Ther. J. Am. Soc. Gene Ther."},{"issue":"13","key":"10.1016\/j.biopha.2025.118274_bib41","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"issue":"48","key":"10.1016\/j.biopha.2025.118274_bib42","doi-asserted-by":"crossref","first-page":"30260","DOI":"10.1016\/S0021-9258(18)43806-9","article-title":"Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity","volume":"269","author":"Graeff","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118274_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2024.134361","article-title":"An NAD(+) with dually modified adenine for labeling ADP-ribosylation-specific proteins","volume":"168","author":"Zhang","year":"2024","journal-title":"Tetrahedron"},{"issue":"7","key":"10.1016\/j.biopha.2025.118274_bib44","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1039\/D1SC06256E","article-title":"Discovery of an NAD(+) analogue with enhanced specificity for PARP1","volume":"13","author":"Zhang","year":"2022","journal-title":"Chem. Sci."},{"issue":"93","key":"10.1016\/j.biopha.2025.118274_bib45","doi-asserted-by":"crossref","first-page":"13843","DOI":"10.1039\/D3CC04343F","article-title":"A ribose-functionalized NAD(+) with versatile activity for ADP-ribosylation","volume":"59","author":"Stephens","year":"2023","journal-title":"Chem. Commun. (Camb. )"},{"issue":"2","key":"10.1016\/j.biopha.2025.118274_bib46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1021\/acschembio.0c00937","article-title":"NAD(+) for profiling poly-ADP-ribosylation-dependent interacting proteins","volume":"16","author":"Lam","year":"2021","journal-title":"ACS Chem. Biol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:48:50Z","timestamp":1754653730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":46,"alternative-id":["S0753332225004688"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118274","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118274"}}